I. Call to Order.................................................................Marty McKay

II. Parliamentary Business .................................................Marty McKay
A. Introduction of Members/Roll Call
B. Approval of November 2, 2016 Meeting Minutes

III. Reports........................................................................Melwyn Wendt
A. Prior Authorization Monthly Report
B. PDL Reflecting November 2, 2016 P&T Committee Recommendations
C. Louisiana Medicaid Preferred Drug List Program Overview and Results Report – January 15, 2017

IV. New Business..............................................................Nina Bandali
A. Therapeutic Class Reviews of Drug Classes/Drug Manufacturer Testimony
   1. Analgesics, Narcotics Long
   2. Analgesics, Narcotics Short
   3. Angiotensin Modulator Combinations
   4. Angiotensin Modulators
   5. Antibiotics, GI
   6. Antibiotics, Inhaled
   7. Antibiotics, Topical
   8. Antibiotics, Vaginal
   9. Anticoagulants
   10. Antiemetic/Antivertigo Agents
   11. Antifungals, Oral
   12. Antifungals, Topical
   13. Antimigraine Agents, Triptans
   14. Antiparasitics, Topical
   15. Antivirals, Oral
   16. Antivirals, Topical
   17. Beta-Blockers
   18. Bladder Relaxant Preparations
   20. BPH Treatments
   21. Calcium Channel Blockers
   22. Cephalosporins and Related Antibiotics
   23. Fluoroquinolones, Oral
24. GI Motility, Chronic
25. Growth Hormone
26. H. Pylori Treatment
27. Hepatitis C Agents
28. Hypoglycemics, Alpha-Glucosidase Inhibitors - New
29. Hypoglycemics, Incretin Mimetics/Enhancers
30. Hypoglycemics, Insulin and Related Agents
31. Hypoglycemics, Meglitinides
32. Hypoglycemics, Metformins - New
33. Hypoglycemics, SGLT2
34. Hypoglycemics, Sulfonylureas
35. Hypoglycemics, TZD
36. Immunosuppressives, Oral
37. Lincosamides/Oxazolidinones/Streptogramins
38. Lipotropics, Other
39. Lipotropics, Statins
40. Macrolides/Ketolides
41. Multiple Sclerosis Agents
42. Nitrofurans Derivatives
43. Opiate Dependence Treatments
44. PAH Agents, Oral and Inhaled
45. Pancreatic Enzymes
46. Phosphate Binders
47. Pituitary Suppressive Agents, LHRH
48. Platelet Aggregation Inhibitors
49. Proton Pump Inhibitors
50. Sinus Node Inhibitors - New
51. Skeletal Muscle Relaxants
52. Tetracyclines
53. Ulcerative Colitis Agents
54. Vasodilators, Coronary

V. New Single Drug Reviews.........................................................Nina Bandali
55. Alzheimer’s Agents – Namzaric Dose Pack
56. Cytokine and CAM Antagonists – Inflectra Vial
57. Emollients – Dexeryl
58. Immnomodulators, Atopic Dermatitis – Eucrisa
59. Intranasal Rhinitis Agents - Flonase
60. Ophthalmics, Anti-Inflammatory – Bromsite
61. Ophthalmics, Anti-Inflammatory/Immunomodulator – Restasis Multidose
62. Steroids, Topical, High - Ellzia Pak
63. Steroids, Topical Low – Micort – HC
64. Stimulants and Related Agents - Vyvanse Chewable Tablet

VI. Other Business
VII. Next Steps
   A. Proposed Therapeutic Classes to be Reviewed at Next Meeting

VIII. Next Meeting Date – October 25, 2017 or November 1, 2017

IX. Public Testimony